Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 2/20 | 0.47 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CARM1 | Q86X55 | 4/20 | 0.44 |
| ▸ | GLS | O94925 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | GRN | P28799 | 1/20 | 0.42 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20027768 | 0.89 | MAPT (0.52) | MAPTKLKB1ALDH1A1CARM1L3MBTL1 | |
| SCHEMBL29641667 | 0.89 | KMT2A (0.47) | MAPTBRD4KLKB1ALDH1A1CARM1 | |
| SCHEMBL18231857 | 0.89 | KMT2A (0.47) | MAPTBRD4KLKB1ALDH1A1CARM1 | |
| SCHEMBL20027810 | 0.88 | MAPT (0.54) | MAPTBRD4ALDH1A1L3MBTL1GRN | |
| SCHEMBL22897252 | 0.87 | MAPT (0.50) | MAPTBRD4KLKB1ALDH1A1CARM1 | |
| SCHEMBL3836244 | 0.87 | KLKB1 (0.47) | BRD4KLKB1CARM1GLSL3MBTL1 | |
| SCHEMBL18604959 | 0.87 | KLKB1 (0.45) | BRD4KLKB1CARM1 | |
| SCHEMBL4586722 | 0.87 | KLKB1 (0.64) | KLKB1CARM1 | |
| SCHEMBL5475948 | 0.86 | CARM1 (0.48) | MAPTKLKB1ALDH1A1CARM1MAPK14 | |
| SCHEMBL5475957 | 0.86 | CARM1 (0.48) | MAPTKLKB1ALDH1A1CARM1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708332-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708333-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11685721-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20170073314-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708332-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | MAPT 3007/4885BRD4 4510/4885KLKB1 1/4885 |
| US-20170073314-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK5 | MAPT 2830/4885BRD4 4544/4885KLKB1 1/4885 |
| US-11708333-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | MAPT 2685/4885BRD4 4550/4885KLKB1 1/4885 |
| US-11685721-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | MAPT 2984/4885BRD4 4340/4885KLKB1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.